title: European perspective on multiple myeloma treatment strategies: update following recent congresses.
abstract: The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies.
authors.affiliation: Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria. heinz.ludwig@wienkav.at
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Hervé
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
authors.forename: Jamie
authors.initials: J
authors.lastname: Cavenagh
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Faith
authors.initials: F
authors.lastname: Davies
authors.forename: Javier
authors.initials: J
authors.lastname: de la Rubia
authors.forename: Sosana
authors.initials: S
authors.lastname: Delimpasi
authors.forename: Meletios
authors.initials: M
authors.lastname: Dimopoulos
authors.forename: Johannes
authors.initials: J
authors.lastname: Drach
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
authors.forename: Urs
authors.initials: U
authors.lastname: Hess
authors.forename: Ulf-Henrik
authors.initials: UH
authors.lastname: Mellqvist
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Jesús
authors.initials: J
authors.lastname: San-Miguel
authors.forename: Pia
authors.initials: P
authors.lastname: Sondergeld
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
authors.forename: Miklos
authors.initials: M
authors.lastname: Udvardy
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003226:Congresses as Topic; D005060:Europe; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide